Aarti Pharmalabs is currently trading at Rs. 682.95, up by 13.90 points or 2.08% from its previous closing of Rs. 669.05 on the BSE.
The scrip opened at Rs. 660.35 and has touched a high and low of Rs. 692.05 and Rs. 660.35 respectively. So far 5851 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 721.00 on 29-Aug-2024 and a 52 week low of Rs. 380.65 on 14-Mar-2024.
Last one week high and low of the scrip stood at Rs. 692.05 and Rs. 637.90 respectively. The current market cap of the company is Rs. 6189.76 crore.
The promoters holding in the company stood at 46.10%, while Institutions and Non-Institutions held 18.74% and 35.16% respectively.
Aarti Pharmalabs has entered into a Share Subscription and Shareholder’s Agreement with Pro-zeal Green Power (Promoter Company), Special Purpose Vehicle (SPV) formed for developing, constructing, operating and maintaining a solar power plant, for acquisition of 26.25% of the Equity Shares/ Voting Rights of SPV and Compulsory Convertible Debentures.
To meet the green energy needs and optimise the energy costs, the company will acquire 26.25% equity stake in SPV as per Electricity Laws. The said acquisition is expected to be completed within 30 days from the execution of share subscription and shareholders’ agreement. Cost of acquisition is Rs 2.97 crore.
Aarti Pharmalabs (APL) (Formerly known as Aarti Organics) is a leading Indian manufacturer of Pharmaceuticals and Nutraceuticals with a global footprint.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1621.85 |
| Dr. Reddys Lab | 1322.50 |
| Cipla | 1287.55 |
| Zydus Lifesciences | 931.95 |
| Lupin | 2287.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: